AstraZeneca reports Phase 3 trial shows Imfinzi-Padcev combo improves survival in bladder cancer
read at Endpoints ↗Positive readoutPositive
AstraZeneca announced that its Phase 3 study of the immunotherapy Imfinzi combined with the antibody‑drug conjugate Padcev, developed with Pfizer and Astellas, extended overall survival for patients with advanced bladder cancer compared with standard chemotherapy.
The company said it will submit the data to regulators and pursue approval for the combination as a new treatment option for this indication.
The positive result follows a recent Phase 3 success reported by Merck in the same disease area, highlighting growing interest in immunotherapy‑based regimens for bladder cancer.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “AstraZeneca follows Merck with Phase 3 win in bladder cancer”
read at Endpoints ↗82 words · retrieved May 14
comments(0)
5-min edit window · permanent after that